newsfilter
← Latest News
GlobeNewswire·

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

ENTX
  • Entera Bio Ltd. appointed Riccardo Paolo Camisasca, M.D., as Chief Medical Officer.
  • Dr. Camisasca brings over 30 years of global pharmaceutical research & clinical development experience from roles at Sumitomo Pharma, Takeda, & Novartis.
  • His most recent position was Global Head of Research & Development at Sumitomo Pharma Switzerland.
  • The appointment strengthens Entera's clinical execution team ahead of the planned initiation of the EB613 Phase 3 program.
  • EB613 is an oral, once-daily anabolic tablet for osteoporosis being developed as the first oral treatment of its class.
  • A prior Phase 2 study of EB613 met all biomarker & bone mineral density endpoints without significant safety concerns.
  • Entera's pipeline also includes EB612 for hypoparathyroidism, an oral oxyntomodulin for obesity, & an oral GLP-2 tablet for short bowel syndrome.
  • Dr. Camisasca previously led clinical development & medical affairs at Bial & held leadership roles at Syneos Health, Takeda, & Novartis.
  • He earned his Medical Degree with honors & specialized in Clinical Pharmacology at the University of Milan.